Islet Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Islet Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-63,310	Closed	-$924K	–	121
2022 Q2	$924K	Buy	+63,310	New	+$951K	0.09%	104

Other funds holding TARS

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Islet Management's TARS Position: Q3 2022 in Review

Islet Management sold out of Tarsus Pharmaceuticals (TARS) in Q3 2022, closing a stake of 63,310 shares — an estimated $924K sold.

Islet Management first reported a position in TARS in Q2 2022 and held it in 1 quarter. The position peaked at $924K in Q2 2022. 75 funds tracked by Wall St. Rank hold TARS as of Q3 2022.

Islet Management reported no remaining Tarsus Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Islet Management sold 63,310 Tarsus Pharmaceuticals shares in Q3 2022, an estimated $924K.
Islet Management first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Islet Management's Tarsus Pharmaceuticals position peaked at $924K in Q2 2022.
75 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2022.

Based on Islet Management's 13F filing for Q3 2022, filed 14 Nov 2022.